Future studies should explore the possibility of collecting data on dialysis treatment (e.g., type of dialysate, vascular access, and Kt/v), additional clinical outcome measures (urea, prealbumin, and transferrin), and additional comorbidities (only diabetes and hypertension were available in the current study). This evidence concerns the gene TTR and diabetes mellitus.